UK-based Essential Pharma announced that it has acquired the rights to market Bayer’s Ventavis iloprost trometamol inhalation solution for the treatment of primary pulmonary hypertension in all markets except for the US and Russia. Essential said that it has also acquired global rights to the Breelib nebulizer used to deliver the inhalation solution. Financial details were not disclosed.
The company notes that the Ventavis acquisition follows its 2024 acquisition of Teva’s Colobreathe colistimethate sodium inhalation powder as an expansion of its portfolio in the rare cardio-respiratory disease area.
Essential Pharma President Rare Disease and Interim CEO Simon Ball commented, “Adding Ventavis and the Breelib nebuliser to Essential Pharma’s growing rare disease portfolio signals our commitment to enabling continued access to treatments that make a difference to individuals living with niche and rare medical conditions. This acquisition leverages our global commercial footprint and highlights our motivation to invest further into rare diseases, building on our strong reputation as a partner of choice in the biopharmaceutical sector.”
Read the Essential Pharma press release
